Willingness of Older Canadians with HIV to Participate in HIV Cure Research Near and After the End of Life: A Mixed-Method Study.
HIV
HIV cure
end-of-life research
mixed-methods research
research autopsy
Journal
AIDS research and human retroviruses
ISSN: 1931-8405
Titre abrégé: AIDS Res Hum Retroviruses
Pays: United States
ID NLM: 8709376
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
pubmed:
3
7
2022
medline:
11
8
2022
entrez:
2
7
2022
Statut:
ppublish
Résumé
HIV cure research requires interrogating latent HIV reservoirs in deep tissues, which necessitates autopsies to avoid risks to participants. An HIV autopsy biobank would facilitate this research, but such research raises ethical issues and requires participant engagement. This study explores the willingness to participate in HIV cure research at the end of life. Participants include Canadians with HIV [people with HIV (PWHIV)] aged 55 years or older. Following a mixed-method study design, all participants completed a phone or online survey, and a subset of participants participated in in-depth phone or videoconference interviews. We produced descriptive statistics of quantitative data and a thematic analysis of qualitative data. Barriers and facilitators were categorized under domains of the Theoretical Domains Framework. From April 2020 to August 2021, 37 participants completed the survey (mean age = 69.9 years old; mean duration of HIV infection = 28.5 years), including 15 interviewed participants. About three quarters of participants indicated being willing to participate in hypothetical medical studies toward the end of life (
Identifiants
pubmed: 35778845
doi: 10.1089/AID.2022.0006
pmc: PMC9483839
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
670-682Subventions
Organisme : NIAID NIH HHS
ID : P01 AI169609
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062512
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH118120
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH067127
Pays : United States
Références
AIDS Res Hum Retroviruses. 2020 Dec;36(12):1033-1046
pubmed: 32449624
Clin Infect Dis. 2019 Aug 30;69(6):1063-1067
pubmed: 30715211
PLoS One. 2018 Jul 23;13(7):e0199670
pubmed: 30036365
Implement Sci. 2015 Apr 21;10:53
pubmed: 25895742
Nat Med. 2021 Dec;27(12):2085-2098
pubmed: 34848888
Nat Med. 2016 Aug;22(8):839-50
pubmed: 27400264
Eur J Hum Genet. 2021 Jan;29(1):11-19
pubmed: 32737438
AIDS. 2017 Jan 2;31(1):1-4
pubmed: 27755112
Eur J Hum Genet. 2022 Mar;30(3):367-377
pubmed: 34803164
BMC Med Ethics. 2018 Oct 20;19(1):83
pubmed: 30342507
J Virus Erad. 2017 Jan 1;3(1):40-50.e21
pubmed: 28275457
PLoS One. 2021 Apr 1;16(4):e0249141
pubmed: 33793624
JCI Insight. 2017 Aug 3;2(15):
pubmed: 28768913
PLoS One. 2017 Jan 25;12(1):e0170112
pubmed: 28122027
Enferm Infecc Microbiol Clin (Engl Ed). 2019 Jun - Jul;37(6):373-379
pubmed: 30389268
Nat Rev Immunol. 2012 Jul 20;12(8):607-14
pubmed: 22814509
J Virus Erad. 2019 Apr 1;5(2):122-124
pubmed: 31191916
AIDS Res Hum Retroviruses. 2020 Dec;36(12):1071-1082
pubmed: 32449625
Eur J Hum Genet. 2014 Apr;22(4):445-51
pubmed: 23921537
Clin Infect Dis. 2019 Aug 30;69(6):1068-1070
pubmed: 30715193
Clin Infect Dis. 2019 Sep 27;69(8):1345-1352
pubmed: 30561541
J Med Ethics. 2017 Feb;43(2):78-81
pubmed: 27143494
J Virus Erad. 2017 Oct 1;3(4):212-217
pubmed: 29057085
AIDS. 2018 Oct 23;32(16):2279-2289
pubmed: 30102653
Implement Sci. 2017 Jun 21;12(1):77
pubmed: 28637486
Eur J Hum Genet. 2010 Nov;18(11):1261-4
pubmed: 20648060
Nat Biotechnol. 2016 Oct;34(10):1010-1014
pubmed: 27617737
BMC Med Ethics. 2022 Jan 29;23(1):7
pubmed: 35090454
J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):39-46
pubmed: 27028501
Implement Sci. 2012 Apr 24;7:37
pubmed: 22530986
J Clin Invest. 2020 Apr 1;130(4):1699-1712
pubmed: 31910162
AIDS Care. 2010 Nov;22(11):1403-9
pubmed: 20936540